TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava.

Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information.

Highlights TCT 2019

Researchers analyzed the 5-year follow-up results for the EXCEL trial, which randomized 948 patients with an intermediate or low SYNTAX score to undergo angioplasty with an everolimus-eluting stent (XIENCE, Abbott Vascular) while others were randomized to coronary artery revascularization surgery.

The primary endpoint at 5 years consisted of death, stroke, or infarction, while the secondary endpoint at 5 years was a composite of death, stroke, infarction, and ischemia-driven revascularization.

Groups were similar: the mean age was 66 years old, most patients were male, and 30% of subjects had diabetes. The SYNTAX score was 20.6 ± 6.2 for local sites and 26.5 ± 6.3 for core lab with angiography. About 80.5% of patients had severe bifurcation lesion in the left main coronary artery.


Read also: TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS.


Over 90% of patients in both groups completed the 5-year follow-up. There were no differences in the primary endpoint (22% for angioplasty and 19.2% for myocardial revascularization surgery; p = 0.13). The secondary endpoint favored myocardial revascularization surgery (24.1% vs. 31.2%; p = 0.002), driven by a higher need for ischemia-driven revascularization (16.9% vs. 10%; p > 0.001). There were no differences as regards cardiac death, infarction, or stroke. Non-cardiac death rates were higher in the angioplasty group.

Conclusion

In patients with unprotected left main coronary artery disease who had intermediate or low anatomical complexity, there were no differences between angioplasty and myocardial revascularization surgery as regards death, stroke, or infarction after a 5-year follow-up.

Courtesy of Dr. Carlos Fava.

Link to the SBHCI Publication HERE

excel

excel-5yearpdf

Original Title: EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.

Author of the Original Title: Gregg W. Stone.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...